Cure My Disease

Don't miss your cure!

 Log in / Sign up

A blood test that foresees heart rhythms?

NCT ID NCT07795892

Diagnosis Sponsor: University of Rzeszow Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

This study asks whether tiny RNA molecules in the blood can signal a higher risk of dangerous heart rhythms in people who have heart failure after a heart attack and use an implanted defibrillator. Researchers collect blood samples from 57 participants and compare RNA patterns between those who do and do not experience a device-treated arrhythmia during remote monitoring. The goal is to find a simple biomarker that could improve how doctors predict and manage arrhythmia risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood sample analysis for small RNA molecules (microRNAs) as biomarkers
What this could lead to
If certain RNA molecules reliably track dangerous heart rhythms, doctors could use a simple blood test to spot high-risk patients earlier and tailor defibrillator care.
What could go wrong
This is a small observational study, so the findings may not apply broadly. The RNA markers might not clearly separate who will have dangerous rhythms, and the results need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

57 people

The number who actually took part.

Started

Mar 2026

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients receiving cardiology outpatient care for post-myocardial infarction heart failure who have an implanted cardioverter-defibrillator or cardiac resynchronization therapy defibrillator and are followed through a remote monitoring program.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Post-myocardial infarction heart failure * Previous implantation of an implantable cardioverter-defibrillator or cardiac resynchronization therapy defibrillator * Participation in a remote monitoring program for the implanted device * Written informed consent Exclusion Criteria: * Age younger than 18 years * Lack of informed consent or withdrawal of consent * Concurrent participation in another study evaluating a drug or therapeutic intervention

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure with reduced ejection fraction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure ventricular fibrillation ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure with reduced ejection fraction Ischemic cardiomyopathy Ventricular arrhythmia

Contacts and locations

Locations

  • Clinical Provincial Hospital No. 2 in Rzeszow

    Rzeszów, Podkarpackie Voivodeship, 35-301, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.